Ramipril FG

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ramipril FG

Quick Facts

Property Description
Active Ingredient Ramipril
Form Tablet, Capsule, Oral Solution
Pharmacological Class ACE Inhibitor (Angiotensin-Converting Enzyme Inhibitor)
Common Use Antihypertensive Agent (for blood pressure control)
Origin Synthetic Prodrug

What is Ramipril FG and its Primary Pharmacological Classification?

Ramipril FG is a specific pharmaceutical preparation containing the synthetic active ingredient Ramipril, which belongs to the class of Angiotensin-Converting Enzyme (ACE) Inhibitors. This classification places it within the primary group of Antihypertensive Agents used for the systemic management of the circulatory system. The core function of Ramipril involves modulating the Renin-Angiotensin-Aldosterone System (RAAS), a crucial hormonal pathway governing blood pressure regulation, making it a foundational drug type for cardiovascular care. This reflects the established therapeutic role of ACE inhibitors in managing hypertension.

The Active Component: Ramipril as a Prodrug

The active ingredient, Ramipril, is administered as a prodrug—an initially inactive compound that requires metabolic conversion within the body to become effective. It undergoes de-esterification, primarily in the liver, to form its highly potent active metabolite, Ramiprilat. Ramipril FG is defined as a single-ingredient product intended for monotherapy. For oral administration, the preparation is commonly available in several dosage forms, predominantly as tablets and capsules. The process of converting to Ramiprilat is a key characteristic, differentiating it from ACE inhibitors that are fully active upon ingestion.

General Purpose of Ramipril as an Antihypertensive Agent

The general purpose of Ramipril FG is to facilitate the relaxation and widening of blood vessels throughout the body, which reduces the overall pressure against which the heart must pump. The potent action of the metabolite Ramiprilat is to competitively inhibit the ACE, thereby suppressing the production of the powerful vasoconstrictor Angiotensin II. This inhibition directly causes vasodilation and a subsequent decrease in Total Peripheral Resistance, which is the foundational therapeutic goal in managing and maintaining healthy blood pressure levels and minimizing circulatory strain. A typical use scenario involves its prescription to adults requiring foundational circulatory support to achieve sustained blood pressure control.

Regulatory References

  1. Ramipril - StatPearls - NCBI Bookshelf

What side effects are possible with Ramipril FG?

Possible Side Effects and Safety Information

The safety profile of Ramipril FG is defined by adverse reactions classified by frequency and grouped into System-Organ Classes (SOCs), as documented in official regulatory sources (EMA, FDA). The most frequently reported effects are classified as common (occurring in 1% to 10% of users), and include non-productive cough, headache, dizziness, hypotension (low blood pressure), and fatigue. Metabolic effects, such as increased blood potassium ( hyperkalemia), are also listed as common.

Uncommon side effects may affect the skin, causing rash or pruritus (itching), or affect the cardiovascular system, leading to tachycardia (increased heart rate) or myocardial ischaemia (reduced blood flow to the heart). Serious adverse reactions explicitly documented in official labels include potentially life-threatening Angioedema (swelling of the face, tongue, or throat), Acute Hepatic Failure, Acute Renal Failure, and blood dyscrasias (severe blood abnormalities).

Safety Constraints and Patterns

The official labeling specifies that hypotension is most likely to occur following the initiation of therapy or after a dosage increase. Furthermore, the medication is contraindicated during the second and third trimesters of pregnancy due to the risk of fetal injury. Ramipril should not be used in individuals with a history of Angioedema related to a previous ACE inhibitor or in patients with significant bilateral renal artery stenosis. Safety monitoring of renal function and serum electrolytes is often noted in official documents.

Overdose and Emergency Response

Official Overdose Profile and When to Seek Help

The documented profile of Ramipril FG overdosage describes an exaggerated extension of the drug’s primary pharmacological effect, resulting in severe physiological consequences. Immediate medical attention must be sought for any suspected overdose.

Documented Overdose Manifestations

Overdosage typically presents with Profound Hypotension (severely low blood pressure), leading to secondary signs such as Dizziness, Syncope (fainting), and Tachycardia (fast heart rate).

Serious/Life-Threatening Outcomes Required Emergency Action
Severe Angioedema (Swelling of face, tongue, or throat) Seek immediate medical attention for suspected overdose.
Hyperkalemia (High potassium levels) Contact emergency services immediately for trouble breathing or throat swelling.
Acute Renal Failure Management is restricted to Symptomatic and Supportive Treatment.

Regulatory Management and Observation

No specific antidote is known for Ramipril overdose. Following the resolution of Angioedema, the official documentation mandates continuous medical observation for at least 12 to 24 hours.

Population-specific notes from regulatory authorities emphasize that use during the second or third trimester of pregnancy is associated with a risk of Fetal Toxicity or death, requiring immediate medical consultation. Patients with Renal Impairment are noted to have increased exposure to the active metabolite, which may increase toxicity risk.

Therapeutic Uses of Ramipril FG

What Ramipril FG Treats: Main Uses and Benefits

Ramipril FG is applied across several relevant therapeutic domains focused on circulatory health and prevention. The medication is commonly used to support patients facing high blood pressure (hypertension), chronic heart failure, and those at high risk for major cardiovascular events, including heart attack and stroke.

Sustained Management and Organ Protection

The therapy is commonly used to address the clinical manifestation of elevated systemic blood pressure, which creates noticeable physiological strain. It is commonly used to support the achievement of sustained blood pressure control, which may assist with maintaining overall circulatory stability and may assist with long-term support for overall functional stability. For patients classified as high risk due to conditions like existing vascular disease or diabetes, its application is relevant in addressing the risk of severe cardiovascular events. Furthermore, Ramipril FG is often applied in the context of established heart damage (e.g., post-MI) and is considered relevant for managing kidney function, which may assist with addressing symptoms related to organ-specific functional stress.

“The medication is relevant in clinical settings marked by increased discomfort or tension, and supports multiple symptom-focused domains.”

Quick Fact: Relief for Sustained Pressure
Commonly Used to Help With: Sustained management of elevated systemic blood pressure.
Key Benefit: Supports circulatory stability and may assist with long-term risk management.

Regulatory References

  1. NIH MedlinePlus overview of Ramipril

Eligibility and Restrictions for Use

Ramipril is an Angiotensin-Converting Enzyme (ACE) inhibitor whose eligibility for use is strictly defined by regulatory authorities based on contraindications and patient-specific conditions.

Populations For Whom Use Is Contraindicated

  • Patients with a history of angioedema (swelling of the face, throat, or tongue) related to prior ACE inhibitor therapy or with hereditary/idiopathic angioedema.
  • Women who are in their second or third trimester of pregnancy (use is also not recommended in the first trimester).
  • Patients with bilateral renal artery stenosis (narrowing of both kidney arteries) or stenosis in a single functioning kidney.
  • Concomitant use with aliskiren in patients with diabetes mellitus or moderate-to-severe renal impairment.
  • Concomitant use with a Neprilysin Inhibitor (e.g., sacubitril/valsartan) or within 36 hours of discontinuing one.

Eligibility-Related Restrictions and Special Populations

  • Pediatric Use: Safety and effectiveness have not been established in children and adolescents, and use is not recommended.
  • Impaired Organ Function: Patients with existing renal or hepatic impairment may require lower starting doses and close medical monitoring.
  • Lactation: Use in nursing mothers is not recommended.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ramipril's interaction profile is primarily defined by its effects on the Renin-Angiotensin System (RAS) and its influence on electrolytes.

Contraindicated Combinations

Certain combinations are strictly prohibited to prevent severe adverse events, including hypotension, hyperkalemia, and increased risk of angioedema. These include:

  • Aliskiren in patients with diabetes mellitus or moderate to severe renal impairment.
  • Angiotensin II Receptor Blockers (ARBs) in patients with diabetic nephropathy.
  • Sacubitril/Valsartan (a Neprilysin Inhibitor). A 36-hour washout period is required when switching to or from Ramipril.
  • Use with certain high-flux dialyser membranes during extracorporeal treatments.

Clinically Significant Interactions

Interacting Agent Category Effect Documented in Official Labeling
Potassium-sparing diuretics / Potassium Supplements Increased risk of hyperkalemia (elevated potassium levels).
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Potential reduction in the antihypertensive effect and increased risk of renal function deterioration.
Other Antihypertensive Agents / Alcohol Increased risk of hypotension (low blood pressure) due to additive effects.
mTOR Inhibitors (e.g., Everolimus) Increased risk of angioedema (severe swelling).

Ramipril may be taken with or without food, as food does not significantly affect the total extent of absorption of the active drug, ramiprilat.

Mechanism of Action

Ramipril is a pro-drug, undergoing hydrolysis in vivo, primarily in the liver, to form its active metabolite, Ramiprilat. Ramiprilat acts as a potent, competitive inhibitor of the somatic Angiotensin-Converting Enzyme (ACE), a metalloprotease also known as Kininase II.

ACE is a key biological target within the Renin-Angiotensin-Aldosterone System (RAAS), tethered to the luminal surface of vascular endothelial cells. By binding to the zinc-binding active site of ACE, Ramiprilat prevents the enzyme from performing its function: the conversion of inactive Angiotensin I to the active vasoconstrictor Angiotensin II.

Intracellularly, the reduced Angiotensin II synthesis lessens the Angiotensin II type 1 ( AT1) receptor signaling on vascular smooth muscle cells and the adrenal cortex. Downstream cascades include decreased AT1-mediated vasoconstriction and diminished aldosterone secretion from the adrenal glands.

System-level physiological consequences involve a modulation of vascular tone, leading to systemic arteriolar vasodilation, and a reduction in fluid retention via aldosterone pathway suppression. Simultaneously, the enzyme's Kininase II function is also inhibited, leading to a decreased breakdown of the vasodilator Bradykinin, further contributing to the downstream cascade of vascular smooth muscle relaxation and systemic total peripheral resistance modulation.

Dosage and Administration Information

Ramipril is an angiotensin-converting enzyme (ACE) inhibitor typically prescribed to treat high blood pressure and heart failure, and to reduce cardiovascular risk after a heart attack or stroke. It is crucial to follow your prescribing healthcare professional’s instructions precisely, as the dose is tailored to your specific condition and response.

Administration Guidelines

  • Timing: Ramipril is usually taken once or twice a day. Try to take your dose at the same time each day. It can be taken with or without food.
  • Swallowing: Swallow the capsule whole with a glass of water. If you are unable to swallow the capsule, you may open it and sprinkle the contents onto a small amount of applesauce or mix it into 4 ounces (120 mL) of water or apple juice. Ensure the entire mixture is consumed completely to receive the full dose. The mixture can be pre-prepared and stored for up to 24 hours at room temperature or 48 hours under refrigeration.
  • Consistency: Do not stop taking Ramipril FG without consulting your doctor, even if you feel well. Controlling your blood pressure is a long-term commitment.

Dose Adjustments and Missed Doses

Your doctor will likely start you on a low dose and gradually increase it, often over several weeks, to find the most effective dose. Regular blood pressure monitoring and lab tests to check kidney function and potassium levels are essential throughout treatment.

Situation Action
Missed Dose Take the missed dose as soon as you remember, unless it is almost time for your next scheduled dose. If so, skip the missed dose and continue your regular dosing schedule. Do not take a double dose.
Initial Dosing The first dose may cause dizziness or lightheadedness, particularly if you are also taking a diuretic or are volume-depleted. Your doctor may recommend taking the first dose at bedtime.

Recent Clinical Evidence

Overview of Clinical Research

Ramipril is an angiotensin-converting enzyme (ACE) inhibitor and its clinical utility has been established through several large-scale, international studies, most notably the Heart Outcomes Prevention Evaluation (HOPE) and the Acute Infarction Ramipril Efficacy (AIRE) trials.

These studies primarily focused on its use beyond lowering blood pressure alone, concentrating on cardiovascular protection in high-risk patients.


Key Findings in Cardiovascular Risk Reduction

1. Prevention in High-Risk Patients (The HOPE Study): A large, long-term, randomized, placebo-controlled trial, the HOPE study, evaluated the use of Ramipril in patients aged 55 or older who were at high risk for major cardiovascular events. These patients had a history of vascular disease or diabetes plus one other risk factor, but were not known to have heart failure or low left ventricular function.

  • The trial findings demonstrated that Ramipril was associated with a reduction in the combined rate of myocardial infarction (heart attack), stroke, and death from cardiovascular causes.
  • This observed benefit was noted across a broad range of patient subgroups.

2. Post-Myocardial Infarction and Heart Failure (The AIRE Study): The AIRE study examined the effect of Ramipril in patients with clinical evidence of heart failure that occurred following a recent acute myocardial infarction.

  • In this population, the study observed that Ramipril was associated with a significant reduction in the risk of all-cause mortality (death) over the follow-up period.
  • The benefit was noted to be sustained in post-trial follow-up assessments.

Frequently Asked Questions (FAQ)

Common questions about Ramipril FG (FAQ)

Q: Can Ramipril FG interact with over-the-counter pain relievers like ibuprofen?

Official product information states that Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which include common pain relievers like ibuprofen, may interact with Ramipril. This interaction is documented to reduce the antihypertensive effect of Ramipril. Furthermore, combining these medications may increase the risk of worsening kidney function, especially in individuals with existing kidney issues.

Q: Why is potassium intake sometimes mentioned with Ramipril FG?

Regulatory documents mention potassium intake because Ramipril is associated with a risk of elevated potassium levels in the blood, a condition known as hyperkalemia. Consuming additional potassium from supplements, salt substitutes, or a diet high in potassium-rich foods may increase this risk. Regulatory caution is noted regarding increased potassium intake, and adjustments to potassium consumption are handled under the direction of a healthcare professional.

Q: Can Ramipril FG be taken with multivitamins?

Since multivitamins or other supplements can sometimes contain high levels of potassium, official guidelines caution about potential risks related to hyperkalemia (high potassium levels in the blood). The consideration of supplements is addressed with a healthcare professional.

Q: Are generic versions of Ramipril FG considered equivalent to the brand name?

Regulatory bodies require generic versions of Ramipril to meet bioequivalence standards established by the authorities. Bioequivalence means the generic drug must be absorbed into the bloodstream at the same rate and to the same extent as the brand-name drug. Regulatory authorities classify generics that meet these standards as therapeutically equivalent.

Q: What foods or supplements should be avoided with Ramipril FG?

According to official documentation, it is necessary to avoid using potassium supplements and salt substitutes that contain potassium. Regulatory documents also recommend against the consumption of moderately high or high dietary potassium intake unless otherwise directed by a physician.

Q: Is a metallic taste or dry mouth a possible side effect of Ramipril FG?

Yes, official reports of adverse reactions indicate that taste disturbance, which can include a metallic taste or loss of taste, has been reported. Dry mouth is also listed among the possible side effects associated with Ramipril.

Q: How quickly does Ramipril FG typically start to show an effect?

Pharmacological studies indicate that while some effects may begin sooner, the full blood pressure-lowering effect of Ramipril is typically apparent within two weeks of starting treatment. The maximal effect is generally attained after about four weeks of continuous use.

Q: What happens if I forget to take Ramipril FG sometimes?

Official instructions for a missed dose are provided within the dosing guidelines for the medication. These instructions detail when to resume the regular schedule and when to skip a missed dose.

Q: Are there different types of Ramipril FG available?

Ramipril is available as a medication containing only the single active ingredient. It is also available in combination with other active substances, most commonly with the diuretic Hydrochlorothiazide, to treat blood pressure and heart conditions.

Q: Is Ramipril FG a 'water pill' or diuretic?

Ramipril is classified as an Angiotensin-Converting Enzyme (ACE) Inhibitor, which acts on the body's hormonal systems to lower blood pressure. It is not classified as a diuretic, which is commonly known as a 'water pill,' although Ramipril is often prescribed together with a diuretic.

Q: Do I need to change my diet while taking Ramipril FG? (Refined to non-potassium/alcohol/NSAID specific advice)

Official health guidelines note that general dietary changes are often considered part of a treatment plan for high blood pressure. Common dietary considerations for managing blood pressure often include limiting salt, fat, and cholesterol, in addition to managing potassium intake.

Q: Can Ramipril FG affect my kidney function?

Regulatory documents indicate that Ramipril may cause or worsen renal impairment in some individuals. Due to this potential, official documents note that monitoring of kidney function is an expected component of therapy.

Q: What is the expected duration of action for Ramipril FG?

Pharmacodynamic studies show that after multiple oral doses, Ramipril's active metabolite maintains a high level of ACE inhibition for at least 24 hours. This duration of action supports its use in a once- or twice-daily dosing regimen for sustained blood pressure control.

Q: Does Ramipril FG have any known sexual side effects?

Official product labeling lists impotence (erectile dysfunction) as an adverse reaction that was reported in clinical trials involving Ramipril.

Q: Do any studies look at the long-term safety profile of Ramipril FG?

Yes, large-scale, long-term clinical trials such as the HOPE study monitored patients for several years. These studies assessed both cardiovascular outcomes and the long-term occurrence of adverse events, with the data being utilized in the drug’s official safety profile.

Q: Does Ramipril FG interact with herbal supplements?

Regulatory authorities note that there is very limited formal clinical data regarding interactions between Ramipril and various herbal remedies or supplements. The disclosure of all supplements and herbal products to a healthcare provider is noted in official documentation.

Q: What are the regulatory classifications of Ramipril FG?

Ramipril is officially classified as an Angiotensin-Converting Enzyme (ACE) Inhibitor. This classification places it in the major therapeutic group of Antihypertensive Agents used for managing blood pressure and other cardiovascular conditions.

Q: Is Ramipril FG known to cause skin rashes?

Official adverse reaction reports confirm that Ramipril can cause skin rashes. Various dermatologic reactions have been reported, including urticaria (hives), photosensitivity (increased sensitivity to sunlight), and, in rare instances, more severe reactions like erythema multiforme.

Q: What common blood tests might be affected by taking Ramipril FG?

Official documents note that serum potassium levels, creatinine, and blood urea nitrogen (BUN)—all markers related to kidney function—can be affected by the medication. These are common laboratory values that are monitored during treatment.

Q: Does Ramipril FG cause changes in mood or anxiety?

Adverse reactions reported in the neuropsychiatric category include anxiety, depression, nervousness, and insomnia, according to official product information.

Q: Is there a certain time of day that Ramipril FG is usually taken? (Morning vs. Evening rationale)

While Ramipril is usually taken once or twice daily at the same time each day, official documents note that taking the first dose at bedtime is sometimes suggested. This specific instruction is given to minimize the impact of the initial blood pressure drop, or hypotension.

Q: Are there any known issues with taking Ramipril FG and alcohol?

Official consumer information warns that alcohol consumption may amplify the blood pressure-lowering effect of Ramipril. This additive effect can increase the possibility of experiencing dizziness, light-headedness, or fainting.

Q: Why might Ramipril FG need to be stopped before surgery?

ACE inhibitors, including Ramipril, may cause intraoperative hypotension (a severe drop in blood pressure during major surgery). The medication is noted to carry a risk of intraoperative hypotension, and temporary cessation is a consideration to mitigate this risk.

Q: Can Ramipril FG affect a person's sleep pattern?

Adverse reaction data indicates that Ramipril can affect sleep. Specifically, insomnia (difficulty falling or staying asleep) and general sleep disturbance are listed among the reported side effects.

How should Ramipril FG be stored and disposed of?

Storage and Disposal of Ramipril

Ramipril must be stored at controlled room temperature, typically defined as 59 F to 86 F (15 C to 30 C). It is mandatory to keep the medication from freezing and to store it away from excessive heat, moisture, and direct light to preserve its stability. The product should be kept in its original, tightly closed container with a safety closure.

Child Safety and Disposal

Official instructions require the medication to be kept out of the sight and reach of children and that safety caps always be locked. For disposal, unused or expired Ramipril must not be thrown into household waste or wastewater; patients should ask a healthcare professional for guidance on proper discarding protocols.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ramipril FG found in:

A-Z Index: